Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash from Investing Activities (2020 - 2025)

Rapid Micro Biosystems' Cash from Investing Activities history spans 6 years, with the latest figure at -$9.6 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 46.57% year-over-year to -$9.6 million; the TTM value through Sep 2025 reached $15.3 million, down 63.39%, while the annual FY2024 figure was $36.7 million, 13.04% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$9.6 million at Rapid Micro Biosystems, down from $9.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $24.8 million in Q2 2024 and bottomed at -$99.5 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is $4.9 million (2024), against an average of -$921368.4.
  • The largest annual shift saw Cash from Investing Activities plummeted 1846.41% in 2022 before it surged 508.63% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$27.1 million in 2021, then surged by 147.31% to $12.8 million in 2022, then dropped by 21.81% to $10.0 million in 2023, then plummeted by 51.41% to $4.9 million in 2024, then plummeted by 297.06% to -$9.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Cash from Investing Activities are -$9.6 million (Q3 2025), $9.3 million (Q2 2025), and $10.7 million (Q1 2025).